Login / Signup

Vaccine Effectiveness Against Severe Disease and Death for Patients With COVID-19 During the Delta-Dominant and Omicron-Emerging Periods: A K-COVE Study.

Yoo-Yeon KimYoung June ChoeJia KimRyu Kyung KimEun Jung JangHyeryeon LeeSeonju YiSang-Won LeeYoung Joon Park
Published in: Journal of Korean medical science (2023)
National cohort data collected during the coronavirus disease 2019 (COVID-19) delta and omicron periods in Korea revealed a lower risk of severe infection in recipients of three doses of the COVID-19 vaccine (adjusted odds ratio [aOR], 0.05-0.08). The risk of death was reduced during the omicron period compared to the delta period (aOR, 0.75; 95% confidence interval, 0.67-0.84).
Keyphrases
  • coronavirus disease
  • sars cov
  • respiratory syndrome coronavirus
  • early onset
  • randomized controlled trial
  • systematic review
  • electronic health record
  • single cell